LMR Partners’s Galectin Therapeutics GALT Stock Holding History

LMR Partners’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$129K	–	1465
2024 Q4	$129K	Buy	+100,000	New	+$240K	﹤0.01%	976

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

LMR Partners's GALT Position: Q3 2021 in Review

LMR Partners sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 19,285 shares — an estimated $62K sold.

LMR Partners first reported a position in GALT in Q2 2015 and held it in 2 quarters. The position peaked at $62K in Q2 2021. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

LMR Partners reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 19,285 Galectin Therapeutics shares in Q3 2021, an estimated $62K.
LMR Partners first reported a position in Galectin Therapeutics in Q2 2015 and held it in 2 quarters.
LMR Partners's Galectin Therapeutics position peaked at $62K in Q2 2021.
70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.